Alexandria Real Estate Equities (ARE) Stock Analysis & Winston Score
Alexandria Real Estate Equities owns and operates office and laboratory buildings that it rents to life science companies, biotech firms, and pharmaceutical companies. These specialized buildings are called "life science campuses" and are designed specifically for scientific research — they have extra ventilation, plumbing, and safety features that normal office buildings do not have. Alexandria is the largest owner of life science real estate in the United States, with major campuses in Boston, San Francisco, San Diego, and New York. The company makes money by collecting rent from its tenants, which include many of the world's largest drug companies and hundreds of smaller biotech startups. As a Real Estate Investment Trust (REIT), it is required to pay out most of its income as dividends to shareholders. Alexandria's main competitive advantage is that life science lab space is expensive and difficult to build, making it hard for competitors to quickly replace what it offers. The biggest risk the company faces is a slowdown in biotech funding, which could reduce demand for new lab space and pressure occupancy rates.
Winston Score: 37/100 — Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Good (15/30)
- Growth: Weak (2/20)
- Cash Flow: Mixed (4/10)
- Stability: Mixed (3/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $50.22
Market Cap: $8.8B
Sector: Real Estate
Industry: REIT - Office
Exchange: New York Stock Exchange


